People
David Wilkinson brings experience of strategy & governance in growth firms
Companies strengthen leadership teams with C-suite and boards of directors appointments, with new hires at Sandoz, Mission Bio, SkinBio, Epic Sciences, and more.
The employees were terminated over allegations of industrial espionage on behalf of the Chinese government. MD Anderson ought to quell concerns of racial profiling following the firings.
Turf cutting for the Bellhouse Building to be performed by Lord & Lady Drayson
Accenture recently published a new report, “New Science: Biopharma’s New Growth Machine.” In it, the report attempts to evaluate the last 20 years of trends in biopharma and use that data to develop projections for the future of the industry.
For the past nine years, Saynor has been with GSK, most recently serving as senior vice president and global head of classic and established medicines.
Bridge Therapeutics, an innovative startup pharmaceutical company developing a practical and safe therapy for chronic pain, is pleased to announce the addition of Edward J. Minskoff to its board of directors.
With 15 years’ bioproduction and cell & gene therapy expertise, Morad El Gueddari will take charge of Yposkesi’s industrial-scale viral vector manufacturing
Ellume Limited is pleased to announce the appointment of David Green as Chief Financial Officer and Company Secretary, and Mark Boyle Chief Business Officer of the Company.
GenFit’s lead product candidate elafibranor snagged Breakthrough Therapy Designation from the U.S. Food and Drug Administration as a treatment for Primary Biliary Cholangitis (PBC) following strong Phase II results that demonstrated the safety and efficacy of the medication.
PRESS RELEASES